Columbia University

Technology Ventures

Immplacate

Immplacate: Patients with acute and chronic immune disorders have an increased risk of death and a reduced quality of life. Mesenchymal stem cells (MSCs) show promise for effectively treating immune disorders, and in clinical trials conducted by others, they have shown few side effects. Immplacate will provide an effective and safe solution, allowing patients to return to a lifestyle closer to before their onset of disease, through the use of its proprietary process of educating mesenchymal stem cells (EMCs). Immplacate’s novel approach will utilize its EMC therapy where 100% of the cells are therapeutic from the moment they are injected. Immplacate was founded by Dr. Gordana Vunjak-Novakovic and Holly Wobma, and is led by life science executive Anthony Curro (CEO).

To learn more about this opportunity, contact:

Beth Kauderer
Technology Licensing Officer
beth.kauderer@columbia.edu